Winrevair Pricing and Availability in Pulmonary Arterial Hypertension Treatment
Priced at €6,660.78 for a 45 mg single-vial kit and up to €17,539.53 for a 60 mg two-vial package, Winrevair (sotatercept) has been presented as the first biological treatment for pulmonary arterial hypertension (PAH), lemoniteurdespharmacies.fr reported. The biologic drug targets the activin signaling pathway to counteract the pathological thickening of pulmonary artery walls that characterizes the condition. Manufactured via recombinant DNA technology in Chinese hamster ovary cells, the medication requires strict refrigeration between 2 and 8 degrees Celsius before reconstitution.
French regulators approve therapy for adult PAH patients
The French Transparency Commission assigned Winrevair an important medical service benefit, known as SMR, alongside a moderate clinical added value rating of ASMR III. Regulators approved the therapy for adult PAH patients classified under World Health Organization functional classes II, III, and IV, when used alongside standard background therapies. The target population across France spans an estimated 3,312 patients.
Clinicians increase regimen to target dose after three weeks
Administration involves a single subcutaneous injection delivered once every three weeks by trained medical staff or by patients and caregivers following proper instruction. Treatment begins at an initial weight-based dose of 0.3 mg per kilogram. Three weeks later, clinicians increase the regimen to the target dose of 0.7 mg per kilogram, provided blood platelet counts and hemoglobin levels remain stable. Patients rotate injection sites with each dose while avoiding scarred, tender, or damaged skin.
Treatment must be postponed if platelet counts drop
Treatment must be postponed for three weeks if hemoglobin climbs excessively or if platelet counts drop below 50 x 10⁹ per liter. Common adverse effects reported in clinical monitoring include nosebleeds, headaches, dilated skin capillaries, diarrhea, dizziness, back pain, and bleeding events.
Winrevair is restricted to hospital prescription and specialists
Distributed under List I status as an orphan drug, Winrevair is restricted to hospital prescription and requires oversight by specialists in pneumology, cardiology, or internal medicine. The treatment carries doping risks and is classified as an exception medication requiring special monitoring. Packaging options include 45 mg and 60 mg boxes containing powder vials, pre-filled solvent syringes, transfer devices, and dosing needles, with all listed prices excluding dispensing fees as stated by MSD.
Frequently Asked Questions About Winrevair
How should the medication be prepared and stored before injection?
Unopened vials must stay refrigerated between 2 and 8 degrees Celsius. Before preparation, the kit must sit at room temperature for 15 minutes, and reconstituted solutions must be used within four hours when kept up to 30 degrees Celsius.
What laboratory thresholds require a delay in treatment administration?
Clinicians must delay the three-week dosing schedule if a patient experiences excessive hemoglobin elevation or if platelet counts fall below 50 x 10⁹ per liter.